• 我要登录|
  • 免费注册
    |
  • 我的丁香通
    • 企业机构:
    • 成为企业机构
    • 个人用户:
    • 个人中心
  • 移动端
    移动端
丁香通 logo丁香实验_LOGO
搜实验

    大家都在搜

      大家都在搜

        0 人通过求购买到了急需的产品
        免费发布求购
        发布求购
        点赞
        收藏
        wx-share
        分享

        Trans-Splicing Vectors Expand the Packaging Limits of Adeno-Associated Virus for Gene Therapy Applications

        互联网

        730
        The limited packaging capacity of adeno-associated virus (AAV) has long been recognized as one of the most troublesome obstacles for the development of this gene delivery system. This size constraint derives from the inherent properties of the wild-type AAV virus. As the smallest DNA virus, the assembly of the AAV capsid can only accommodate a single-strand (ss) DNA molecule of less than 5 kb. Therefore, the majority of AAV-based gene therapy protocols have focused on developing this vector for small disease genes, such as factor IX in hemophilia B. Despite this seemly “narrow” area of application, recombinant AAV (rAAV) has still attracted tremendous interest in the field of gene therapy and has become one of the mainstream vectors on trial for clinical applications. Remarkable therapeutic effects for several common genetic diseases, such as diabetes (1 ) and hemophilia B (2 4 ), have been demonstrated in small and large animal models. Phase I dose-escalation studies in hemophilia B patients presented favorable clinical outcomes in the absence of significant toxicity and germline transmission (5 ). The success of AAV gene therapy relies on several salient features of the vector system, including its high efficiency and persistence of gene transfer. AAV is also one of the safest viral vector systems because of the ability to easily delete all viral genes in the recombinant vector. The wild-type virus is not linked to any known human diseases, and the recombinant vector does not evoke harmful cellular immune response. The remarkable progress in AAV-mediated gene therapy for “small gene diseases” has inspired those in the field to develop AAV vectors for the diseases caused by genes larger than 5 kb. Recent breakthroughs in several laboratories have proven the feasibility of overcoming AAV packaging limitations (6 9 ). In this chapter, we will first review the theoretic basis for this novel AAV vector strategy and then provide detailed working protocols, along with examples, as a guide for generating dual vector trans- splicing systems.
        ad image
        提问
        扫一扫
        丁香实验小程序二维码
        实验小助手
        丁香实验公众号二维码
        扫码领资料
        反馈
        TOP
        打开小程序